The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
RET Proto-Oncogene: A Review and Update of Genotype–Phenotype Correlations in Hereditary Medullary Thyroid Cancer and Associated Endocrine Tumors
Abstract
Hereditary medullary thyroid carcinoma (MTC) is caused by autosomal dominant gain-of-function mutations in the RET proto-oncogene. Associations between specific RET mutations (genotype) and the aggressiveness of MTC and presence or absence of other endocrine neoplasms (phenotype) are well documented. Mutations in six exons (10, 11, 13, 14, 15, and 16) located in either cysteine-rich or tyrosine kinase domains cause one of three distinctive clinical subtypes: familial MTC, multiple endocrine neoplasia (MEN) type 2A (including variants with Hirschsprung's disease and cutaneous lichen amyloidosis), and MEN 2B. Hallmarks of MEN 2A include MTC, pheochromocytoma, and hyperparathyroidism. MEN 2B is associated with an earlier onset of MTC and pheochromocytoma, the absence of hyperparathyroidism, and the presence of striking physical stigmata (e.g., coarse facies, ganglioneuromatosis, and marfanoid habitus). Familial MTC is not associated with other endocrine neoplasms; however, the accurate distinction between familial MTC and MEN 2A may be difficult in kindreds with small size, incomplete histories, or a predominance of young individuals who may not have yet fully manifested the syndrome. Genetic testing detects greater than 95% of mutation carriers and is considered the standard of care for all first-degree relatives of patients with newly diagnosed MTC. Recommendations on the timing of prophylactic thyroidectomy and the extent of surgery are based upon a model that utilizes genotype- phenotype correlations to stratify mutations into three risk levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
(2011) · SpringerReference · doi:10.1007/springerreference_33432 · Cited by 2,510
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
Brandi, M. L. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.12.5658 · Cited by 2,031
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
The GDNF family: Signalling, biological functions and therapeutic value
Airaksinen, M. S., & Saarma, M. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn812 · Cited by 1,828
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B. U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,367
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
Jing, S., Wen, D., Yu, Y., Holst, P. L., Luo, Y., Fang, M., Tamir, R., Antonio, L., Hu, Z., Cupples, R., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81311-2 · Cited by 1,174
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
Characterization of a multicomponent receptor for GDNF
Treanor, J. J. S., Goodman, L., de Sauvage, F., Stone, D. M., Poulsen, K. T., Beck, C. D., Gray, C., Armanini, M. P., Pollock, R. A., Hefti, F., et al. (1996) · Nature · doi:10.1038/382080a0 · Cited by 1,080
Grieco, M., Santoro, M., Berlingieri, M. T., Melillo, R. M., Donghi, R., Bongarzone, I., Pierotti, M. A., Della Ports, G., Fusco, A., & Vecchiot, G. (1990) · Cell · doi:10.1016/0092-8674(90)90659-3 · Cited by 959
Activation of a novel human transforming gene, ret, by DNA rearrangement
Takahashi, M., Ritz, J., & Cooper, G. M. (1985) · Cell · doi:10.1016/0092-8674(85)90115-1 · Cited by 854
Activation of RET as a Dominant Transforming Gene by Germline Mutations of MEN2A and MEN2B
Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., et al. (1995) · Science · doi:10.1126/science.7824936 · Cited by 841
Expression of the c-ret proto-oncogene during mouse embryogenesis
Pachnis, V., Mankoo, B., & Costantini, F. (1993) · Development · doi:10.1242/dev.119.4.1005 · Cited by 837
Gilliland, F. D., Hunt, W. C., Morris, D. M., & Key, C. R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<564::aid-cncr20>3.0.co;2-0 · Cited by 803
Mutations of the RET proto-oncogene in Hirschsprung's disease
Edery, P., Lyonnet, S., Mulligan, L. M., Pelet, A., Dow, E., Abel, L., Holder, S., Nihoul-Fékété, C., Ponder, B. A. J., & Munnich, A. (1994) · Nature · doi:10.1038/367378a0 · Cited by 749
Neurturin, a relative of glial-cell-line-derived neurotrophic factor
Kotzbauer, P. T., Lampe, P. A., Heuckeroth, R. O., Golden, J. P., Creedon, D. J., Johnson Jr, E. M., & Milbrandt, J. (1996) · Nature · doi:10.1038/384467a0 · Cited by 710
Romeo, G., Ronchetto, P., Luo, Y., Barone, V., Seri, M., Ceccherini, I., Pasini, B., Bocciardi, R., Lerone, M., Kääriäinen, H., et al. (1994) · Nature · doi:10.1038/367377a0 · Cited by 700
Kebebew, E., Ituarte, P. H. G., Siperstein, A. E., Duh, Q.-Y., & Clark, O. H. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000301)88:5<1139::aid-cncr26>3.0.co;2-z · Cited by 684
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
Mulligan, L. M., Eng, C., Healey, C. S., Clayton, D., Kwok, J. B. J., Gardner, E., Ponder, M. A., Frilling, A., Jackson, C. E., Lehnert, H., et al. (1994) · Nature Genetics · doi:10.1038/ng0194-70 · Cited by 652
Carlson, K. M., Dou, S., Chi, D., Scavarda, N., Toshima, K., Jackson, C. E., Wells, S. A., Goodfellow, P. J., & Donis-Keller, H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1579 · Cited by 600
Baloh, R. H., Tansey, M. G., Lampe, P. A., Fahrner, T. J., Enomoto, H., Simburger, K. S., Leitner, M. L., Araki, T., Johnson, E. M., & Milbrandt, J. (1998) · Neuron · doi:10.1016/s0896-6273(00)80649-2 · Cited by 588
Early Malignant Progression of Hereditary Medullary Thyroid Cancer
Machens, A., Niccoli-Sire, P., Hoegel, J., Frank-Raue, K., van Vroonhoven, T. J., Roeher, H.-D., Wahl, R. A., Lamesch, P., Raue, F., Conte-Devolx, B., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa012915 · Cited by 545
Eng, C., SmIth, D. P., MullIgan, L. M., Nagal, M. A., Healey, C. S., Ponder, M. A., Gardner, E., Scheumann, G. F. W., Jackson, C. E., Tunnacllffe, A., et al. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.2.237 · Cited by 537
Persephin, a Novel Neurotrophic Factor Related to GDNF and Neurturin
Milbrandt, J., de Sauvage, F. J., Fahrner, T. J., Baloh, R. H., Leitner, M. L., Tansey, M. G., Lampe, P. A., Heuckeroth, R. O., Kotzbauer, P. T., Simburger, K. S., et al. (1998) · Neuron · doi:10.1016/s0896-6273(00)80453-5 · Cited by 495
GDNF Family Neurotrophic Factor Signaling: Four Masters, One Servant?
Airaksinen, M. S., Titievsky, A., & Saarma, M. (1999) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1999.0754 · Cited by 477
The GDNF family ligands and receptors — implications for neural development
Baloh, R. H., Enomoto, H., Johnson, E. M., & Milbrandt, J. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(99)00048-3 · Cited by 475
Lips, C., Landsvater, R. M., Hoppener, J., Geerdink, R. A., Blijham, G., van Veen, J. M. J.-S., van Gils, A., de Wit, M. J., Zewald, R. A., Berends, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409293311302 · Cited by 454
The GDNF/RET signaling pathway and human diseases
Takahashi, M. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00012-0 · Cited by 446
Takahashi, M., Buma, Y., Iwamoto, T., Inaguma, Y., Ikeda, H., & Hiai, H. (1988) · PubMed · Cited by 442
A genetic study of Hirschsprung disease.
Badner, J. A., Sieber, W. K., Garver, K. L., & Chakravarti, A. (1990) · PubMed · Cited by 433
Mechanism of Activation of the ret Proto-oncogene by Multiple Endocrine Neoplasia 2A Mutations
Asai, N., Iwashita, T., Matsuyama, M., & Takahashi, M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.3.1613 · Cited by 340
RET Proto-Oncogene in the Development of Human Cancer
Eng, C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.380 · Cited by 339
The RET Proto-Oncogene in Multiple Endocrine Neoplasia Type 2 and Hirschsprung's Disease
Eng, C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609263351307 · Cited by 328
Trupp, M., Scott, R., Whittemore, S. R., & Ibáñez, C. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.30.20885 · Cited by 318
Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease
Attié, T., Pelet, A., Edery, P., Eng, C., Mulligan, L. M., Amiel, J., Boutrand, L., Beldjord, C., Nihoul-Fékété, C., Munnich, A., et al. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.8.1381 · Cited by 312
Early Diagnosis of Medullary Carcinoma of the Thyroid Gland by Means of Calcitonin Assay
Melvin, K. E. W., Miller, H. H., & Tashjian, A. H. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111112852004 · Cited by 297
Sanicola, M., Hession, C., Worley, D., Carmillo, P., Ehrenfels, C., Walus, L., Robinson, S., Jaworski, G., Wei, H., Tizard, R., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6238 · Cited by 296
Somatic mutations in the RET proto‐oncogene in sporadic medullary thyroid carcinoma
Marsh, D. J., Learoyd, D. L., Andrew, S. D., Krishnan, L., Pojer, R., Richardson, A., Delbridge, L., Eng, C., & Robinson, B. G. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.681503.x · Cited by 279
Segregation at three loci explains familial and population risk in Hirschsprung disease
Gabriel, S. B., Salomon, R., Pelet, A., Angrist, M., Amiel, J., Fornage, M., Attié-Bitach, T., Olson, J. M., Hofstra, R., Buys, C., et al. (2002) · Nature Genetics · doi:10.1038/ng868 · Cited by 275
de Leon, M. P. (1994) · Recent Results in Cancer Research · doi:10.1007/978-3-642-85076-9_7 · Cited by 260
Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis
de Graaff, E., Srinivas, S., Kilkenny, C., D'Agati, V., Mankoo, B. S., Costantini, F., & Pachnis, V. (2001) · Genes & Development · doi:10.1101/gad.205001 · Cited by 251
Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease
Angrist, M., Bolk, S., Thiel, B., Puffenberger, E. G., Hofstra, R. M., Buys, C. H. C. M., Cass, D. T., & Chakravarti, A. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.5.821 · Cited by 241
Creedon, D. J., Tansey, M. G., Baloh, R. H., Osborne, P. A., Lampe, P. A., Fahrner, T. J., Heuckeroth, R. O., Milbrandt, J., & Johnson, E. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.7018 · Cited by 227
Tsuzuki, T., Takahashi, M., Asai, N., Iwashita, T., Matsuyama, M., & Asai, J. (1995) · PubMed · Cited by 225
Segouffin-Cariou, C., & Billaud, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.5.3568 · Cited by 223
Hayashi, H., Ichihara, M., Iwashita, T., Murakami, H., Shimono, Y., Kawai, K., Kurokawa, K., Murakumo, Y., Imai, T., Funahashi, H., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203799 · Cited by 223
Eng, C., & Mulligan, L. M. (1997) · Human Mutation · doi:10.1002/(sici)1098-1004(1997)9:2<97::aid-humu1>3.0.co;2-m · Cited by 212
Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma
Wohllk, N. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.10.3740 · Cited by 204
Ichihara, M. (2004) · Cancer Letters · doi:10.1016/s0304-3835(03)00456-7 · Cited by 197
Routine Measurement of Plasma Calcitonin in Nodular Thyroid Diseases
Vierhapper, H. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.5.1589 · Cited by 192
Germline mutation of RET codon 883 in two cases of de novo MEN 2B
Smith, D. P., Houghton, C., & Ponder, B. A. (1997) · Oncogene · doi:10.1038/sj.onc.1201481 · Cited by 189
Tahira, T., Ishizaka, Y., Itoh, F., Sügimura, T., & Nagao, M. (1990) · PubMed · Cited by 180
The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors
Koch, C. A., Pacak, K., & Chrousos, G. P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021069 · Cited by 177
Eng, C., Mulligan, L. M., Smith, D. P., Healey, C. S., Frilling, A., Raue, F., Neumann, H. P. H., Ponder, M. A., & Ponder, B. A. J. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb01903.x · Cited by 173
Eng, C., Crossey, P. A., Mulligan, L. M., Healey, C. S., Houghton, C., Prowse, A., Chew, S. L., Dahia, P. L., O'Riordan, J. L., & Toledo, S. P. (1995) · Journal of Medical Genetics · doi:10.1136/jmg.32.12.934 · Cited by 172
Soler, R. M., Dolcet, X., Encinas, M., Egea, J., Bayascas, J. R., & Comella, J. X. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-21-09160.1999 · Cited by 172
Pheochromocytoma in multiple endocrine neoplasia type 2: European study
Modigliani, E., VASEN, H. M., RAUE, K., DRALLE, H., FRILLING, A., GHERI, R. G., BRANDI, M. L., LIMBERT, E., NIEDERLE, B., FORGAS, L., et al. (1995) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1995.tb01211.x · Cited by 172
Worby, C. A., Vega, Q. C., Zhao, Y., Chao, H. H.-J., Seasholtz, A. F., & Dixon, J. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.39.23619 · Cited by 168
HENNESSY, J. F., WELLS, S. A., ONTJES, D. A., & COOPER, C. W. (1974) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-39-3-487 · Cited by 158
Borrego, S., Sáez, M. E., Ruiz, A., Gimm, O., López-Alonso, M., Antiñolo, G., & Eng, C. (1999) · Journal of Medical Genetics · doi:10.1136/jmg.36.10.771 · Cited by 146
Miyauchi, A., Futami, H., Hai, N., et al. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00658.x · Cited by 145
Frequency of RET mutations in long- and short-segment Hirschsprung disease
Seri, M., Yin, L., Barone, V., Bolino, A., Celli, I., Bocciardi, R., Pasini, B., Ceccherini, I., Lerone, M., Kristoffersson, U., et al. (1997) · Human Mutation · Cited by 139
Chiariello, M., Visconti, R., Carlomagno, F., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1201778 · Cited by 131
Block, M. A., Jackson, C. E., Greenawald, K. A., Yott, J. B., & Tashjian, A. H. (1980) · Archives of Surgery · doi:10.1001/archsurg.1980.01380020012004 · Cited by 128
Pierchala, B. A., Milbrandt, J., & Johnson, E. M. (2002) · Neuron · doi:10.1016/s0896-6273(01)00585-2 · Cited by 128
Surgical management of hereditary pheochromocytoma1
Yip, L., Lee, J. E., Shapiro, S. E., Waguespack, S. G., Sherman, S. I., Hoff, A. O., Gagel, R. F., Arens, J. F., & Evans, D. B. (2004) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2003.12.001 · Cited by 127
Self-citationThe Long and Short Isoforms of Ret Function as Independent Signaling Complexes
Pierchala, B. A., Ahrens, R. C., Crowder, R. J., Milbrandt, J., & Johnson, E. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203580200 · Cited by 115
Advances and Controversies in the Diagnosis and Management of Medullary Thyroid Carcinoma
Heshmati, H. M., Gharib, H., van Heerden, J. A., & Sizemore, G. W. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00024-7 · Cited by 113
Gastrointestinal Manifestations of Multiple Endocrine Neoplasia Type 2
Cohen, M. S., Phay, J. E., Albinson, C. H., DeBenedetti, M. K., Skinner, M. A., Lairmore, T. C., Doherty, G. M., Balfe, D. M., Wells, S. A., & Moley, J. F. (2002) · Annals of Surgery · doi:10.1097/00000658-200205000-00006 · Cited by 110
Glial Cell Line-derived Neurotrophic Factor Induces Ret-mediated Lamellipodia Formation
van Weering, D. H. J., & Bos, J. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.1.249 · Cited by 108
Borrego, S., Wright, F. A., Fernández, R. M., Williams, N., López-Alonso, M., Davuluri, R. V., Antiñolo, G., & Eng, C. (2003) · The American Journal of Human Genetics · doi:10.1086/345466 · Cited by 101
Fitze, G., Cramer, J. P., Ziegler, A., Schierz, I. A. M., Schreiber, M., Kuhlisch, E., Roesner, D., & Schackert, H. K. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08218-1 · Cited by 101
Murakami, H., Iwashita, T., Asai, N., Shimono, Y., Iwata, Y., Kawai, K., & Takahashi, M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1186 · Cited by 96
Webb, T. A., Sheps, S. G., & Carney, J. A. (1980) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198004000-00003 · Cited by 92
Takahashi, M., Iwashita, T., Santoro, M. M., Lyonnet, S., Lenoir, G., & Billaud, M. (1999) · Human Mutation · Cited by 91
Pheochromocytoma: Inherited associations, bilaterality, and cortex preservation
Inabnet, W. B., Caragliano, P., & Pertsemlidis, D. (2000) · Surgery · doi:10.1067/msy.2000.110846 · Cited by 88
Murakami, H., Iwashita, T., Asai, N., Iwata, Y., Narumiya, S., & Takahashi, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202514 · Cited by 80
A Two-Hit Model for Development of Multiple Endocrine Neoplasia Type 2B by RET Mutations
Iwashita, T., Murakami, H., Kurokawa, K., Kawai, K., Miyauchi, A., Futami, H., Qiao, S., Ichihara, M., & Takahashi, M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2227 · Cited by 72
Beldjord, C., Desclaux-Arramond, F., Raffin‐Sanson, M., Corvol, J., de Keyzer, Y., LUTON, J. P., Plouin, P., & BERTAGNA, X. Y. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.7.7608256 · Cited by 71
Characterization of Ret-Shc-Grb2 Complex Induced by GDNF, MEN 2A, and MEN 2B Mutations
Ohiwa, M., Murakami, H., Iwashita, T., Asai, N., Iwata, Y., Imai, T., Funahashi, H., Takagi, H., & Takahashi, M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7225 · Cited by 67
Donghi, R., Sozzi, G., Pierotti, M. A., Biunno, I., Miozzo, M. R., Fusco, A., Grieco, M., Santoro, M. M., Vecchio, G., & Spurr, N. (1989) · PubMed · Cited by 67
Borrego, S., Eng, C., Sánchez, B., Sáez, M. E., González, E. N., & Antiñolo, G. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5093 · Cited by 65
Signal Transduction Pathways Activated by RET Oncoproteins in PC12 Pheochromocytoma Cells
Xing, S., Furminger, T. L., Tong, Q., & Jhiang, S. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.4909 · Cited by 61
Mutations in the RET protooncogene in sporadic pheochromocytomas
Lindor, N. M., Honchel, R., Khosla, S., & Thibodeau, S. N. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.2.7852530 · Cited by 61
Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells.
van Weering, D. H. J., Medema, J. P., Puijenbroek, A. V., et al. (1995) · PubMed · Cited by 54
Ethnic Differences in the HFE Codon 282 (Cys/Tyr) Polymorphism
Beckman, L. E., Saha, N., Va, S., Landeghem, V., & Beckman, L. E. (1997) · Human Heredity · doi:10.1159/000154422 · Cited by 51
Ret-mediated mitogenesis requires Src kinase activity.
Melillo, R. M., Barone, M. V., Lupoli, G., Cirafici, A. M., Carlomagno, F., Visconti, R., Matoskova, B., Fiore, P. P. D., Vecchio, G., Fusco, A., et al. (1999) · PubMed · Cited by 48
Borrego, S. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.9.3361 · Cited by 44
Kitamura, Y., Scavarda, N. J., Wells, S. A., Jackson, C. E., & Goodfellow, P. J. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.10.1987 · Cited by 40
Feng, L., Wang, C.-Y., Jiang, H., Oho, C., Dugich‐Djordjevic, M. M., Mei, L., & Lu, B. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00129-3 · Cited by 38
Akhand, A. A., Ikeyama, T., Akazawa, S., Kato, M., Hossain, K., Takeda, K., Suzuki, H., Takahashi, M., & Nakashima, I. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6731 · Cited by 10
Cited by
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
Self-citationChen, H., Sippel, R. S., O'Dorisio, M. S., Vinik, A. I., Lloyd, R. V., & Pacak, K. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb4f0 · Cited by 593
Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity
Dahia, P. L. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3648 · Cited by 545
Geographic influences in the global rise of thyroid cancer
Kim, J., Gosnell, J. E., & Roman, S. A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0263-x · Cited by 473
Qin, Y., & Hurley, L. H. (2008) · Biochimie · doi:10.1016/j.biochi.2008.02.020 · Cited by 450
Metadata
- Authors
- Kouvaraki, M. A., Shapiro, S. E., Perrier, N. D., Cote, G. J., Gagel, R. F., Hoff, A. O., Sherman, S. I., Lee, J. E., & Evans, D. B.
- Venue
- Thyroid
- Publisher
- SAGE Publications
- Published
- 2005-06
- Volume
- 15
- Issue
- 6
- Pages
- 531-544
- ISSN
- 1050-7256 (ISSN-L)
- 1557-9077
- OpenAlex
- W2159075642
- Cited by
- 288
- References
- 93
- FWCI
- 11.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.